Junshi Biosciences chairman reaches midpoint of shareholding increase plan

Shanghai Junshi Biosciences Co., Ltd. announced that its chairman, Mr. Xiong Jun, who is also a controlling shareholder and actual controller, has reached the midpoint of his plan to increase his shareholding in the company. As of October 11, 2025, Mr. Xiong Jun had not yet executed any share purchases, despite the plan aiming for a total increase of no less than RMB100 million in both A and H shares, with at least RMB50 million allocated for A shares. The original plan commenced on April 12, 2025, and is set to continue for 12 months.

The company stated that the delay is attributed to a combination of factors, including the window period for periodic reporting, equity incentive matters, and funding arrangements. Mr. Xiong Jun currently holds 87,856,618 shares, representing 8.56% of the company's total share capital.

Despite the current status, Mr. Xiong Jun remains committed to the shareholding increase plan, citing confidence in the company's operational development and growth potential. He intends to proceed with increasing his shareholdings during the remaining period of the plan as opportunities arise, and the company will continue to monitor and disclose the progress.